Home › Funds › 1290 Funds › 1290 Essex Small Cap Growth Fund
Fund family: 1290 Funds · Filed by 1290 Funds (CIK 1605941) · SEC series S000076802
Share classes and tickers: ESCFX (C000236850), ESCJX (C000236852), ESCKX (C000236849)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 769 with, 0 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as 1290 Funds’s manager page (13,565 ballot items across 6 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | 1290 Funds | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 85.3% | 748 | 91.7% | 11,367 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 7.7% | 284 |
No item-level comparison with other 1290 Funds funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 82.8% of this fund’s 769 such votes could be given a sector; the other 132 (17.2%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Industrials | 145 | 0 | 0.0% |
| Consumer Discretionary | 142 | 0 | 0.0% |
| Health Care | 124 | 0 | 0.0% |
| Technology | 82 | 0 | 0.0% |
| Finance | 55 | 0 | 0.0% |
| Energy | 38 | 0 | 0.0% |
| Telecommunications | 18 | 0 | 0.0% |
| Miscellaneous | 14 | 0 | 0.0% |
| Real Estate | 12 | 0 | 0.0% |
| Consumer Staples | 7 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 512 | 0 |
| Audit-related | 102 | 0 |
| Say-on-Pay | 90 | 0 |
| Compensation | 48 | 0 |
| Corporate Governance | 20 | 0 |
| Capital Structure | 6 | 0 |
| Extraordinary Transactions | 2 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | June 5, 2026 | $3M | 4 | 0 |
| Xeris Biopharma Holdings, Inc. | June 4, 2026 | $3M | 4 | 0 |
| Globalstar, Inc. | May 13, 2026 | $2M | 4 | 0 |
| Xometry, Inc. | June 16, 2026 | $2M | 5 | 0 |
| Leonardo DRS, Inc. | May 14, 2026 | $2M | 11 | 0 |
| Travere Therapeutics, Inc. | May 19, 2026 | $2M | 14 | 0 |
| Lincoln Educational Services Corporation | May 7, 2026 | $2M | 12 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $2M | 11 | 0 |
781 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)
In the 2025-2026 proxy season, 1290 Essex Small Cap Growth Fund (ESCFX) voted at 100 shareholder meetings of 100 companies, on 781 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times. It voted FOR the board's own proposals less often than 1290 Funds's funds as a whole (85.3% against 91.7%).
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of 1290 Funds’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.